Stay updated on Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial page.
Latest updates to the Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial page
- Check5 days agoChange DetectedNo additions or deletions detected on the page; the content remains unchanged.SummaryDifference0.1%
- Check12 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check34 days agoChange DetectedRemoved the government funding status notice and related operating-status links from the page.SummaryDifference0.4%
- Check48 days agoChange DetectedThe changes between the old and new pages are non-significant, with core study information unchanged and only minor UI or formatting adjustments observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
- Check55 days agoChange DetectedOnly minor UI/layout differences are visible between the screenshots. No core content like study details, eligibility criteria, or outcomes appears to have changed.SummaryDifference0.1%
- Check70 days agoChange DetectedNo significant changes detected.SummaryDifference0.5%
Stay in the know with updates to Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of CAN04 and Pembrolizumab in Solid Tumors Clinical Trial page.